What Happened

ADC Therapeutics reported positive topline results from its Phase 3 LOTIS-5 trial, evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study met its primary endpoint of progression-free survival (PFS) with statistical significance and showed no detrimental effect on overall survival (OS).

Who Is Affected

This trial impacts hematology/oncology providers treating r/r DLBCL patients, particularly those who cannot access or progress on CAR-T therapies. Patients aged 75+ showed higher rates of serious adverse events (SAEs) in the test arm.

Market Impact

• ZYNLONTA® plus rituximab demonstrated a higher complete response (CR) rate (39.5% vs. 26.7%) and longer duration of CRs (16.8 months vs. 12.3 months) compared to the control arm.
• The study addresses an unmet need in r/r DLBCL treatment, potentially expanding the market for ADC Therapeutics.

What to Watch

ADC Therapeutics plans to discuss the benefit-risk profile with the FDA and file a supplemental Biologics License Application (sBLA). Sales reps should monitor FDA updates and prepare for potential adoption in hematology/oncology accounts.